DrugPatentWatch Database Preview
Par Pharm Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for PAR PHARM INC, and what generic alternatives to PAR PHARM INC drugs are available?
PAR PHARM INC has forty-three approved drugs.
There is one US patent protecting PAR PHARM INC drugs. There are nine tentative approvals on PAR PHARM INC drugs.
There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-nine supplementary protection certificates in twelve countries.
Drugs and US Patents for Par Pharm Inc
Expired US Patents for Par Pharm Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 5,294,636 | Start Trial |
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 6,143,775 | Start Trial |
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 4,859,692 | Start Trial |
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 5,583,152 | Start Trial |
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 5,482,963 | Start Trial |
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 5,612,367 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 10 mg and 20 mg | ➤ Subscribe | 2008-02-29 |
International Patents for Par Pharm Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 1948613 | Start Trial |
Japan | 2008538560 | Start Trial |
Mexico | 2007013118 | Start Trial |
Japan | 5378788 | Start Trial |
Canada | 2605413 | Start Trial |
World Intellectual Property Organization (WIPO) | 2006115626 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1915993 | C300625 | Netherlands | Start Trial | PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414 |
0443983 | 2007C/043 | Belgium | Start Trial | PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222 |
2236132 | 122015000006 | Germany | Start Trial | PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718 |
2101777 | 93081 | Luxembourg | Start Trial | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
0785926 | 08C0041 | France | Start Trial | PRODUCT NAME: AMBRISENTAN; REGISTRATION NO/DATE: EU/1/08/451/001-004 20080421 |
0526708 | 0290017-3 | Sweden | Start Trial | PRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.